The VANIR Study for RSV Vaccine Research
Respiratory Syncytial Virus (RSV) is a highly infectious virus that can cause respiratory illness in all age groups, but it can be especially severe in older adults. RSV often begins with a fever and cold symptoms that may lead to more severe infections and conditions such as bronchiolitis, chronic obstructive pulmonary disease, pneumonia, asthma, and respiratory failure.
In the VANIR Study, we want to see if the study vaccine, called MVA-BN-RSV, can help protect seniors from severe or acute respiratory infection from RSV.
You may be able to join this study if you:
- Are 60 years of age or older
- Are in good general health, or have mild to moderate conditions that are well-managed
- Are comfortable using an app on a mobile phone or other device to report symptoms and communicate with the study team once a month